...
首页> 外文期刊>Cornea >Long-term Outcomes of Living-Related Conjunctival Limbal Allograft Compared With Keratolimbal Allograft in Patients With Limbal Stem Cell Deficiency
【24h】

Long-term Outcomes of Living-Related Conjunctival Limbal Allograft Compared With Keratolimbal Allograft in Patients With Limbal Stem Cell Deficiency

机译:与肢体干细胞缺乏症患者的长期与角抗原同种异体移植相比,生物相关结膜恒星同膜的长期结果

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To compare the long-term outcomes of living-related conjunctival limbal allograft (lr-CLAL) with keratolimbal allograft (KLAL) in patients with limbal stem cell deficiency. Methods: A retrospective, comparative, interventional cohort of patients with bilateral total limbal stem cell deficiency who underwent surgical treatment with a KLAL or lr-CLAL procedure alone (not combined with any other ocular surface stem cell transplantation procedures) with a minimum follow-up of 1 year and who received systemic immunosuppression. Ocular surface stability, best-corrected visual acuity (BCVA), and postoperative complications at the last follow-up were the main outcome measures. Results: There were 224 eyes that underwent KLAL alone and 63 eyes that underwent lr-CLAL alone, with a mean follow-up time for all eyes of 7.2 years (range 1.0-16.0 years). For lr-CLAL eyes, 82.5% maintained a stable ocular surface compared with 64.7% of KLAL eyes at the last follow-up. Only 6.3% of lr-CLAL eyes demonstrated a failed ocular surface compared with 15.6% of KLAL eyes. The mean BCVA was 20/158 for KLAL eyes compared with 20/100 for lr-CLAL eyes at the last follow-up. A smaller proportion of lr-CLAL eyes (30.2% compared with 43.3%) developed an episode of acute rejection, and a higher proportion of these episodes resolved with treatment in the lr-CLAL group (79.0% compared with 53.6%). Conclusions: lr-CLAL demonstrates lower rejection rates, improved graft survival, and better BCVA compared with KLAL. Both careful preoperative donor selection and triple-agent systemic immunosuppression (including tapered systemic corticosteroids) are critical to optimizing the ocular surface stem cell transplantation outcomes.
机译:目的:将活性相关结膜峰同种异体移植(LR-Clal)的长期结果与Keratolimbal同种异体移植(KLAL)进行止血性干细胞缺乏症的患者。方法:一种单独的klal或lr-clal手术(不与任何其他眼部干细胞移植手术组合)接受手术治疗的双侧总爆腹干细胞缺乏患者的回顾性,比较,介入副群体1年,接受全身免疫抑制。眼部表面稳定性,最佳矫正视力(BCVA)以及最后一次随访的术后并发症是主要的结果措施。结果:有224只眼睛,单独接受klal和63只眼睛,单独接受LR-Clal,所有眼睛的平均随访时间为7.2年(1.0-16.0岁)。对于LR-Clal的眼睛,82.5%保持稳定的眼表面,而最后随访的64.7%的klal眼睛。只有6.3%的LR-Clal眼睛表现出未发生的眼表面,与15.6%的klal眼睛相比。平均BCVA为klal眼睛的20/158,而Lr-clal眼睛的目前在最后一次随访中为20/158。 LR-Clal眼睛的比例较小(与43.3%相比)开发了急性排斥反应的一集,并且在LR-Clal基团中处理的这些发作的比例较高(79.0%,而与53.6%相比)。结论:与Klal相比,LR-Clal证明了降低的抑制率,改善的移植物存活,更好的BCVA。仔细的术前供体选择和三元蛋白全身免疫抑制(包括锥形全身皮质类固醇)对于优化眼表面干细胞移植结果至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号